Usefulness of Microbiological Tests in Community-Acquired Pneumonia

Status Recruiting

Clinical Trial Summary

The hypothesis is that community-acquired pneumonia is usually a monomicrobial infection. Therefore, early detection of the etiology allows to select the most active, narrow-spectrum, and cheap, and less toxic antibiotic agent.

Clinical Trial Description

In community-acquired pneumonia, identification of the etiologic agent has theoretically important advantages. For individual patients, it facilitates the administration of a targeted, narrow-spectrum antibiotic therapy that may improve the efficacy of treatment, and reduces risks of antibiotic-related toxicity. For the community, microbiologic results contribute to understanding the local microbial epidemiology of community-acquired pneumonia and the antimicrobial resistance patterns of pathogens, information that is essential in the instauration or modification of empiric treatment regimens.

Guidelines recommend that all admitted patients with community-acquired pneumonia should have a collection of two sets of blood cultures, a good quality sputum sample for Gram stain and culture, a sample of pleural fuid if present and, for severe patients, an urine sample for antigen detection. In contrast, several prospective studies (usually without include urinary tests) concluded that these microbiological studies have limited value in the management of patients admitted with community-acquired pneumonia.

In addition, microbiological studies could provide erroneous or incomplete information. Thus, investigations has showed false-positive results from pneumococcal antigen detection in urine caused by a frequent persistence of positivity after infection or a nasopharyngeal or bronchial colonization. Other authors suggested that community-acquired pneumonia is a polymicrobial infection; consequently, despite the detection of a true microorganism, treatment needs to be also addressed against other potential pathogenic agents.

The purpose of the study is to assess the clinical and the economic derived from the initial microbiological studies, including antigen detection tests in urine for Streptococcus pneumoniae and Legionella pneumophila, in patients with community-acquired pneumonia.

The hypothesis is that community-acquired pneumonia is usually a monomicrobial infection. Therefore, early detection of the etiology allows to select the most active, narrow-spectrum, and cheap, and less toxic antibiotic agent. ;

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00312741
Study type	Observational
Source	Hospital Arnau de Vilanova
Contact	Miquel Falguera, M.D.
Phone	0034-973248100
Email	mfalguera@comll.cat
Status	Recruiting
Phase	N/A
Start date	April 2006
Completion date	May 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05722938` - Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Phase 3
Terminated	`NCT04972318` - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia	N/A
Recruiting	`NCT06065618` - Characteristics of Hospitalized Patients With Community-acquired Pneumonia
Not yet recruiting	`NCT03675178` - Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia	Phase 4
Not yet recruiting	`NCT04166110` - Antibiotic Therapy In Respiratory Tract Infections	N/A
Completed	`NCT02380352` - Short-course Antimicrobial Therapy for Paediatric Respiratory Infections	Phase 4
Completed	`NCT01671280` - Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)	N/A
Completed	`NCT02555852` - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	N/A
Recruiting	`NCT00752947` - Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors	Phase 4
Completed	`NCT00140023` - Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia	Phase 3
Recruiting	`NCT04089787` - Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia	Phase 4
Completed	`NCT05356494` - Postural Drainage and PEP Technique in Community Acquired Pneumonia	N/A
Completed	`NCT05133752` - Oral Nemonoxacin in Treating Elderly Patients With CAP	Phase 4
Not yet recruiting	`NCT06291012` - Stopping Pneumonia Antibiotherapy Regimen Early	Phase 4
Recruiting	`NCT05002192` - A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Completed	`NCT03452826` - Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia	N/A
Terminated	`NCT04071041` - Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.	Phase 3
Completed	`NCT03474991` - KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP	Phase 3
Completed	`NCT01723644` - Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia	N/A
Completed	`NCT01683487` - Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.	Phase 4